CD19-targeted chimeric antigen receptor (CAR) T cell therapy has shown significant promise in clinical trials for individuals with severe lupus. This process involves reengineering a patient’s …

2024年2月21日 · Here, we present data on the short- and long-term efficacy and safety of CD19 CAR T-cell treatment in 15 patients with severe forms of three distinct autoimmune diseases.

4 天之前 · The pharma is working on CD19 NEX-T, an investigational CAR T therapy designed to seek out the cell surface protein CD19, which is highly expressed in B cells. Once it binds to …

2025年3月4日 · CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has achieved marvelous results in the treatment of patients with relapsed and/or refractory B-cell …

1 天前 · Building on its autologous CD19 CAR-T cell therapy obe-cel, Autolus added a CD22 CAR to create AUTO1/22. The dual mechanism is intended to address a major cause of treatment …

2025年2月13日 · Off-the-shelf, allogeneic CD19 chimeric antigen receptor (CAR) T cell products may improve access to treatment versus autologous ones. We report the phase 1 experience …

2024年11月5日 · CD19 chimeric antigen receptor (CAR) T-cell therapy emerged as a novel treatment in autoimmune diseases. Refractory autoimmune hemolytic anemia (rAIHA) is …

2025年1月16日 · CD19-directed chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy elicits high response rates but fails to induce durable responses in most adults with relapsed …

2024年8月27日 · Third-generation chimeric antigen receptor T cells (CARTs) for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) may improve efficacy compared to second …

2025年2月28日 · On April 18, 2024, the FDA mandated the inclusion of a boxed warning for T-cell malignancies following treatment with BCMA-/CD19-directed autologous CAR-T cell …

2016年6月30日 · Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B …

2019年4月22日 · A new anti-CD19 CAR T cell therapy induces potent antitumor responses without causing severe cytokine-release syndrome or neurotoxicity in patients with lymphoma.

2024年10月2日 · The development of a fatal, clonal, autonomously proliferating CD4−CD8− chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after …

CD19-targeted chimeric antigen receptors (CD19 CARs) have opened a path for novel immune therapies in oncology and other fields of medicine. This therapeutic innovation is predicated on …

2025年3月1日 · In B-cell lymphoma, CD19 CAR-NK cells co-expressing IL-15 and CCL-21 (15 × 21 CAR-NK) showed superior cytotoxicity and cytokine secretion functions, and were proven …

2023年2月22日 · In pivotal trials, CD19-CAR therapy outperformed standard of care (SOC) as second line therapy for LBCL 10, 11, and was highly effective as a first line therapy 12, paving …

1 天前 · Engineered cell therapies, such as CD19-targeted chimeric antigen receptor (CAR) T cells, involve reengineering a patient’s own T cells to recognize and attack cells that cause …

2024年6月1日 · The distance between T cells and target cells was identified as the key element in triggering robust CAR-T-cell activity. However, nearly all CD19/CD22-bispecific CARs reported …

Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application.

2024年11月5日 · Recent experience suggests that CD19-CAR T-cell therapy represents a potentially transformative new therapy approach achieving lasting, treatment-free remission in …

This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). Here, we review published phase 1 trials of T cells expressing …

2017年12月14日 · CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 天前 · Schließlich konnte die CAR-T-Zell-Therapie mit Tisagenlecleucel (CD19-CAR) nach Lymphodepletion 140 Tage nach T‑Zell-Apherese im August 2022 gestartet werden. Der …

We report cryo-EM structures of CD19 antigen with the binder FMC63 which is used in four FDA-approved CAR T cell therapies (Kymriah, Yescarta, Tecartus, Breyanzi), and the binder …

Bristol Myers Squibb is exploring use of CD19-directed CAR T-cell therapy in autoimmune diseases, including systemic lupus erythematosus (SLE). 4-6 BMS is developing CD19 NEX-T …

2018年1月31日 · CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long …

We developed a CAR-containing a humanized anti-CD19 scFv domain and a 4-1BB costimulatory domain (huCART19) with the goal of overcoming potential barriers to prolonged persistence.

2024年2月1日 · In this issue of Blood, Abramson et al 1 present follow-up data from TRANSCEND, redemonstrating robust and ongoing responses from the largest pivotal cohort …

2022年6月30日 · Three autologous anti-CD19 CAR T-cell products are currently approved by the US Food and Drug Administration (FDA) as third-line treatment and beyond for patients with …